MDT
HealthcareMedtronic plc
$97.36
+$1.31 (+1.36%)
Jan 5, 2026
Price History (1Y)
Analysis
Medtronic plc is a leading global healthcare company operating in the medical devices industry. The company has a substantial market presence with a market capitalization of $124.88 billion and a revenue of $34.76 billion (TTM). With over 95,000 employees, Medtronic is one of the largest companies in its sector. From a financial perspective, Medtronic has demonstrated strong profitability metrics, including a gross margin of 65.6%, an operating margin of 20.3%, and a profit margin of 13.7%. The company's returns on equity (ROE) and assets (ROA) are 9.8% and 4.7%, respectively, indicating a healthy return on investment. Medtronic also maintains a balance sheet with $29.10 billion in debt and $8.33 billion in cash, resulting in a debt-to-equity ratio of 59.56. Medtronic's valuation is characterized by a price-to-earnings (P/E) ratio of 26.03 (TTM), which reflects the company's growth prospects. With revenue growth rates of 6.6% and earnings growth rates of 8.1%, Medtronic has demonstrated a steady increase in its financial performance. Additionally, the company offers a dividend yield of 296.0%, although this is largely offset by a payout ratio of 76.4%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Medtronic plc
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems and sensors, and InPen, a smart insulin pen. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.
Visit website →Key Statistics
- Market Cap
- $124.88B
- P/E Ratio
- 26.03
- 52-Week High
- $106.33
- 52-Week Low
- $79.55
- Avg Volume
- 6.60M
- Beta
- 0.73
- Dividend Yield
- 296.00%
Company Info
- Industry
- Medical Devices
- Exchange
- NYQ
- Country
- Ireland
- Employees
- 95,000